Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2004-12

AUTHORS

Lin Xu, Susan C Fagan, Jennifer L Waller, David Edwards, Cesar V Borlongan, Jianqing Zheng, William D Hill, Giora Feuerstein, David C Hess

ABSTRACT

BACKGROUND: Minocycline, a semi-synthetic tetracycline antibiotic, is an effective neuroprotective agent in animal models of cerebral ischemia when given in high doses intraperitoneally. The aim of this study was to determine if minocycline was effective at reducing infarct size in a Temporary Middle Cerebral Artery Occlusion model (TMCAO) when given at lower intravenous (IV) doses that correspond to human clinical exposure regimens. METHODS: Rats underwent 90 minutes of TMCAO. Minocycline or saline placebo was administered IV starting at 4, 5, or 6 hours post TMCAO. Infarct volume and neurofunctional tests were carried out at 24 hr after TMCAO using 2,3,5-triphenyltetrazolium chloride (TTC) brain staining and Neurological Score evaluation. Pharmacokinetic studies and hemodynamic monitoring were performed on minocycline-treated rats. RESULTS: Minocycline at doses of 3 mg/kg and 10 mg/kg IV was effective at reducing infarct size when administered at 4 hours post TMCAO. At doses of 3 mg/kg, minocycline reduced infarct size by 42% while 10 mg/kg reduced infarct size by 56%. Minocycline at a dose of 10 mg/kg significantly reduced infarct size at 5 hours by 40% and the 3 mg/kg dose significantly reduced infarct size by 34%. With a 6 hour time window there was a non-significant trend in infarct reduction. There was a significant difference in neurological scores favoring minocycline in both the 3 mg/kg and 10 mg/kg doses at 4 hours and at the 10 mg/kg dose at 5 hours. Minocycline did not significantly affect hemodynamic and physiological variables. A 3 mg/kg IV dose of minocycline resulted in serum levels similar to that achieved in humans after a standard 200 mg dose. CONCLUSIONS: The neuroprotective action of minocycline at clinically suitable dosing regimens and at a therapeutic time window of at least 4-5 hours merits consideration of phase I trials in humans in view of developing this drug for treatment of stroke. More... »

PAGES

7

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1471-2377-4-7

DOI

http://dx.doi.org/10.1186/1471-2377-4-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1032588447

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15109399


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1109", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Neurosciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Models, Animal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Evaluation, Preclinical", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infarction, Middle Cerebral Artery", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ischemic Attack, Transient", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Minocycline", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neurologic Examination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neuroprotective Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rats", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rats, Sprague-Dawley", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Charlie Norwood VA Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.413830.d", 
          "name": [
            "Department of Neurology, Medical College of Georgia, 30912, Augusta, GA, USA", 
            "VA Medical Center, 30904, Augusta, GA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xu", 
        "givenName": "Lin", 
        "id": "sg:person.01223307407.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01223307407.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Georgia", 
          "id": "https://www.grid.ac/institutes/grid.213876.9", 
          "name": [
            "University of Georgia School of Pharmacy, 30912, Augusta, GA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fagan", 
        "givenName": "Susan C", 
        "id": "sg:person.01115504701.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115504701.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Augusta University", 
          "id": "https://www.grid.ac/institutes/grid.410427.4", 
          "name": [
            "Biostatistics and Bioinformatics, Medical College of Georgia, 30912, Augusta, GA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Waller", 
        "givenName": "Jennifer L", 
        "id": "sg:person.01363476023.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363476023.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wayne State University", 
          "id": "https://www.grid.ac/institutes/grid.254444.7", 
          "name": [
            "Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 48202, Detroit, MI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Edwards", 
        "givenName": "David", 
        "id": "sg:person.01315561614.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315561614.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Charlie Norwood VA Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.413830.d", 
          "name": [
            "Department of Neurology, Medical College of Georgia, 30912, Augusta, GA, USA", 
            "VA Medical Center, 30904, Augusta, GA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Borlongan", 
        "givenName": "Cesar V", 
        "id": "sg:person.012440130244.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012440130244.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Augusta University", 
          "id": "https://www.grid.ac/institutes/grid.410427.4", 
          "name": [
            "Department of Neurology, Medical College of Georgia, 30912, Augusta, GA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zheng", 
        "givenName": "Jianqing", 
        "id": "sg:person.0645256706.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645256706.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Augusta University", 
          "id": "https://www.grid.ac/institutes/grid.410427.4", 
          "name": [
            "Department of Cell Biology and Anatomy, Medical College of Georgia, 30912, Augusta, GA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hill", 
        "givenName": "William D", 
        "id": "sg:person.01031470730.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01031470730.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "MSD (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417993.1", 
          "name": [
            "Department of Cardiovascular Diseases, Merck Research Laboratories, 19486, West Point, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Feuerstein", 
        "givenName": "Giora", 
        "id": "sg:person.01317467302.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317467302.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Charlie Norwood VA Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.413830.d", 
          "name": [
            "Department of Neurology, Medical College of Georgia, 30912, Augusta, GA, USA", 
            "VA Medical Center, 30904, Augusta, GA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hess", 
        "givenName": "David C", 
        "id": "sg:person.01146362542.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01146362542.60"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0378-4347(99)00547-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001228029"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/brain/awg178", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004968542"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1006/nbdi.2002.0487", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006449164"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-198815060-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008048905", 
          "https://doi.org/10.2165/00003088-198815060-00001"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.1832501100", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010666269"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2377-2-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015910425", 
          "https://doi.org/10.1186/1471-2377-2-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.str.32.6.1349", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016185576"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.96.23.13496", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019053748"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0006-8993(02)04045-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022970218"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0006-8993(02)04045-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022970218"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.expneurol.2003.12.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029509680"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0006-8993(97)00580-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030416401"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmra022366", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031327510"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.95.26.15769", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035665084"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ana.10553", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043880101"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/417074a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044223162", 
          "https://doi.org/10.1038/417074a"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/417074a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044223162", 
          "https://doi.org/10.1038/417074a"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ana.10242", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049255426"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1089/089771503770195867", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059201655"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/01.wnl.0000058760.13152.1a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064345067"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/01.wnl.0000058760.13152.1a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064345067"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/01.wnl.0000058760.13152.1a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064345067"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/01.wnl.0000058760.13152.1a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064345067"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4049/jimmunol.166.12.7527", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074829796"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1523/jneurosci.22-05-01763.2002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1075009286"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2004-12", 
    "datePublishedReg": "2004-12-01", 
    "description": "BACKGROUND: Minocycline, a semi-synthetic tetracycline antibiotic, is an effective neuroprotective agent in animal models of cerebral ischemia when given in high doses intraperitoneally. The aim of this study was to determine if minocycline was effective at reducing infarct size in a Temporary Middle Cerebral Artery Occlusion model (TMCAO) when given at lower intravenous (IV) doses that correspond to human clinical exposure regimens.\nMETHODS: Rats underwent 90 minutes of TMCAO. Minocycline or saline placebo was administered IV starting at 4, 5, or 6 hours post TMCAO. Infarct volume and neurofunctional tests were carried out at 24 hr after TMCAO using 2,3,5-triphenyltetrazolium chloride (TTC) brain staining and Neurological Score evaluation. Pharmacokinetic studies and hemodynamic monitoring were performed on minocycline-treated rats.\nRESULTS: Minocycline at doses of 3 mg/kg and 10 mg/kg IV was effective at reducing infarct size when administered at 4 hours post TMCAO. At doses of 3 mg/kg, minocycline reduced infarct size by 42% while 10 mg/kg reduced infarct size by 56%. Minocycline at a dose of 10 mg/kg significantly reduced infarct size at 5 hours by 40% and the 3 mg/kg dose significantly reduced infarct size by 34%. With a 6 hour time window there was a non-significant trend in infarct reduction. There was a significant difference in neurological scores favoring minocycline in both the 3 mg/kg and 10 mg/kg doses at 4 hours and at the 10 mg/kg dose at 5 hours. Minocycline did not significantly affect hemodynamic and physiological variables. A 3 mg/kg IV dose of minocycline resulted in serum levels similar to that achieved in humans after a standard 200 mg dose.\nCONCLUSIONS: The neuroprotective action of minocycline at clinically suitable dosing regimens and at a therapeutic time window of at least 4-5 hours merits consideration of phase I trials in humans in view of developing this drug for treatment of stroke.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1471-2377-4-7", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2692582", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2560345", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1024950", 
        "issn": [
          "1471-2377"
        ], 
        "name": "BMC Neurology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "4"
      }
    ], 
    "name": "Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats", 
    "pagination": "7", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "9b3faa1fe72bdc43cc6d90a827eeaf6660772accdb80b59f2fa1b5e4641fd999"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15109399"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100968555"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1471-2377-4-7"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1032588447"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1471-2377-4-7", 
      "https://app.dimensions.ai/details/publication/pub.1032588447"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T23:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8693_00000513.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F1471-2377-4-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1471-2377-4-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1471-2377-4-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1471-2377-4-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1471-2377-4-7'


 

This table displays all metadata directly associated to this object as RDF triples.

266 TRIPLES      21 PREDICATES      64 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1471-2377-4-7 schema:about N05735a14d1074ba3bf47cfe5de8bfcfe
2 N1effd4c0f4474cdfb45ef8e80a749a50
3 N3003cffa736a48ea95f1674f0dd2c83d
4 N38400bfa77004c6abe7bc46d13264129
5 N5811273078df4980b85ec521d18dbd04
6 N8179b15870a44e20860ecc5277b4d269
7 N90bbfb98e4eb4aa58106b75c00675af6
8 N9920e093d29d45aeb39939d8257529f5
9 N9d0bdda5897e4923bb3c59598b7a2677
10 Nb3416b4067ad4ea9832afd90acf97e1a
11 Nd61f9dc2b92e41b6b8d698d1fd70c95e
12 Ne1b71c29c0254c6db2e3e0772f0d8d24
13 Nee0968896ec34c1a960bab77bd1ba0df
14 Nf42200a3610c4a60ba969b54e31fef14
15 Nfe59d166a24a4d6fabe4e5141e7191cb
16 anzsrc-for:11
17 anzsrc-for:1109
18 schema:author Ncd9acfcb7f5d4d8b97262f73c60f5c47
19 schema:citation sg:pub.10.1038/417074a
20 sg:pub.10.1186/1471-2377-2-2
21 sg:pub.10.2165/00003088-198815060-00001
22 https://doi.org/10.1002/ana.10242
23 https://doi.org/10.1002/ana.10553
24 https://doi.org/10.1006/nbdi.2002.0487
25 https://doi.org/10.1016/j.expneurol.2003.12.006
26 https://doi.org/10.1016/s0006-8993(02)04045-3
27 https://doi.org/10.1016/s0006-8993(97)00580-5
28 https://doi.org/10.1016/s0378-4347(99)00547-2
29 https://doi.org/10.1056/nejmra022366
30 https://doi.org/10.1073/pnas.1832501100
31 https://doi.org/10.1073/pnas.95.26.15769
32 https://doi.org/10.1073/pnas.96.23.13496
33 https://doi.org/10.1089/089771503770195867
34 https://doi.org/10.1093/brain/awg178
35 https://doi.org/10.1161/01.str.32.6.1349
36 https://doi.org/10.1212/01.wnl.0000058760.13152.1a
37 https://doi.org/10.1523/jneurosci.22-05-01763.2002
38 https://doi.org/10.4049/jimmunol.166.12.7527
39 schema:datePublished 2004-12
40 schema:datePublishedReg 2004-12-01
41 schema:description BACKGROUND: Minocycline, a semi-synthetic tetracycline antibiotic, is an effective neuroprotective agent in animal models of cerebral ischemia when given in high doses intraperitoneally. The aim of this study was to determine if minocycline was effective at reducing infarct size in a Temporary Middle Cerebral Artery Occlusion model (TMCAO) when given at lower intravenous (IV) doses that correspond to human clinical exposure regimens. METHODS: Rats underwent 90 minutes of TMCAO. Minocycline or saline placebo was administered IV starting at 4, 5, or 6 hours post TMCAO. Infarct volume and neurofunctional tests were carried out at 24 hr after TMCAO using 2,3,5-triphenyltetrazolium chloride (TTC) brain staining and Neurological Score evaluation. Pharmacokinetic studies and hemodynamic monitoring were performed on minocycline-treated rats. RESULTS: Minocycline at doses of 3 mg/kg and 10 mg/kg IV was effective at reducing infarct size when administered at 4 hours post TMCAO. At doses of 3 mg/kg, minocycline reduced infarct size by 42% while 10 mg/kg reduced infarct size by 56%. Minocycline at a dose of 10 mg/kg significantly reduced infarct size at 5 hours by 40% and the 3 mg/kg dose significantly reduced infarct size by 34%. With a 6 hour time window there was a non-significant trend in infarct reduction. There was a significant difference in neurological scores favoring minocycline in both the 3 mg/kg and 10 mg/kg doses at 4 hours and at the 10 mg/kg dose at 5 hours. Minocycline did not significantly affect hemodynamic and physiological variables. A 3 mg/kg IV dose of minocycline resulted in serum levels similar to that achieved in humans after a standard 200 mg dose. CONCLUSIONS: The neuroprotective action of minocycline at clinically suitable dosing regimens and at a therapeutic time window of at least 4-5 hours merits consideration of phase I trials in humans in view of developing this drug for treatment of stroke.
42 schema:genre research_article
43 schema:inLanguage en
44 schema:isAccessibleForFree true
45 schema:isPartOf Na840fbc6dd2942e3b609bddc5183ce60
46 Nce5016bb309f44e5a06737f2b15865d3
47 sg:journal.1024950
48 schema:name Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats
49 schema:pagination 7
50 schema:productId N3be89fe1cae04adda42e475c2fe5e613
51 N61bdfa42e67f47df9e48587e05d1822a
52 N9303769a01114a86a829224fca6ca3cb
53 N97563b9cbbe8429b9837830e6c6d1622
54 Na5df9fef4a9a4990a5575e483be269c4
55 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032588447
56 https://doi.org/10.1186/1471-2377-4-7
57 schema:sdDatePublished 2019-04-10T23:24
58 schema:sdLicense https://scigraph.springernature.com/explorer/license/
59 schema:sdPublisher N7c43acea46ed406198209b6ffc22191a
60 schema:url http://link.springer.com/10.1186%2F1471-2377-4-7
61 sgo:license sg:explorer/license/
62 sgo:sdDataset articles
63 rdf:type schema:ScholarlyArticle
64 N05735a14d1074ba3bf47cfe5de8bfcfe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Treatment Outcome
66 rdf:type schema:DefinedTerm
67 N1effd4c0f4474cdfb45ef8e80a749a50 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Disease Models, Animal
69 rdf:type schema:DefinedTerm
70 N27f1406587ca4b018fd36a3f5302688e rdf:first sg:person.01115504701.99
71 rdf:rest Nc99273a59830403db9cf1e522ef77b15
72 N3003cffa736a48ea95f1674f0dd2c83d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Rats
74 rdf:type schema:DefinedTerm
75 N38400bfa77004c6abe7bc46d13264129 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Time Factors
77 rdf:type schema:DefinedTerm
78 N3be89fe1cae04adda42e475c2fe5e613 schema:name readcube_id
79 schema:value 9b3faa1fe72bdc43cc6d90a827eeaf6660772accdb80b59f2fa1b5e4641fd999
80 rdf:type schema:PropertyValue
81 N3c85e30e9711475f95b5ec6e31684ebb rdf:first sg:person.01031470730.29
82 rdf:rest N4eb61250d0ba4af9bd140cc9286abaed
83 N4eb61250d0ba4af9bd140cc9286abaed rdf:first sg:person.01317467302.28
84 rdf:rest Na117d40e8fd74903a4adc9f14cdb57b5
85 N5811273078df4980b85ec521d18dbd04 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Dose-Response Relationship, Drug
87 rdf:type schema:DefinedTerm
88 N61bdfa42e67f47df9e48587e05d1822a schema:name pubmed_id
89 schema:value 15109399
90 rdf:type schema:PropertyValue
91 N7c43acea46ed406198209b6ffc22191a schema:name Springer Nature - SN SciGraph project
92 rdf:type schema:Organization
93 N8179b15870a44e20860ecc5277b4d269 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Rats, Sprague-Dawley
95 rdf:type schema:DefinedTerm
96 N90bbfb98e4eb4aa58106b75c00675af6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Male
98 rdf:type schema:DefinedTerm
99 N9303769a01114a86a829224fca6ca3cb schema:name doi
100 schema:value 10.1186/1471-2377-4-7
101 rdf:type schema:PropertyValue
102 N97563b9cbbe8429b9837830e6c6d1622 schema:name dimensions_id
103 schema:value pub.1032588447
104 rdf:type schema:PropertyValue
105 N9920e093d29d45aeb39939d8257529f5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Animals
107 rdf:type schema:DefinedTerm
108 N9d0bdda5897e4923bb3c59598b7a2677 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Drug Evaluation, Preclinical
110 rdf:type schema:DefinedTerm
111 Na117d40e8fd74903a4adc9f14cdb57b5 rdf:first sg:person.01146362542.60
112 rdf:rest rdf:nil
113 Na5df9fef4a9a4990a5575e483be269c4 schema:name nlm_unique_id
114 schema:value 100968555
115 rdf:type schema:PropertyValue
116 Na840fbc6dd2942e3b609bddc5183ce60 schema:volumeNumber 4
117 rdf:type schema:PublicationVolume
118 Nb3416b4067ad4ea9832afd90acf97e1a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Ischemic Attack, Transient
120 rdf:type schema:DefinedTerm
121 Nc99273a59830403db9cf1e522ef77b15 rdf:first sg:person.01363476023.25
122 rdf:rest Nf11d45a5c5464d7f9604b9eb5b3c8f07
123 Ncab897f005664ccc83ad5fd6f6088a63 rdf:first sg:person.012440130244.71
124 rdf:rest Ne479e844796d4d3e9adeaef43375e20d
125 Ncd9acfcb7f5d4d8b97262f73c60f5c47 rdf:first sg:person.01223307407.93
126 rdf:rest N27f1406587ca4b018fd36a3f5302688e
127 Nce5016bb309f44e5a06737f2b15865d3 schema:issueNumber 1
128 rdf:type schema:PublicationIssue
129 Nd61f9dc2b92e41b6b8d698d1fd70c95e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Neuroprotective Agents
131 rdf:type schema:DefinedTerm
132 Ne1b71c29c0254c6db2e3e0772f0d8d24 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Neurologic Examination
134 rdf:type schema:DefinedTerm
135 Ne479e844796d4d3e9adeaef43375e20d rdf:first sg:person.0645256706.29
136 rdf:rest N3c85e30e9711475f95b5ec6e31684ebb
137 Nee0968896ec34c1a960bab77bd1ba0df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Minocycline
139 rdf:type schema:DefinedTerm
140 Nf11d45a5c5464d7f9604b9eb5b3c8f07 rdf:first sg:person.01315561614.71
141 rdf:rest Ncab897f005664ccc83ad5fd6f6088a63
142 Nf42200a3610c4a60ba969b54e31fef14 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Injections, Intravenous
144 rdf:type schema:DefinedTerm
145 Nfe59d166a24a4d6fabe4e5141e7191cb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Infarction, Middle Cerebral Artery
147 rdf:type schema:DefinedTerm
148 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
149 schema:name Medical and Health Sciences
150 rdf:type schema:DefinedTerm
151 anzsrc-for:1109 schema:inDefinedTermSet anzsrc-for:
152 schema:name Neurosciences
153 rdf:type schema:DefinedTerm
154 sg:grant.2560345 http://pending.schema.org/fundedItem sg:pub.10.1186/1471-2377-4-7
155 rdf:type schema:MonetaryGrant
156 sg:grant.2692582 http://pending.schema.org/fundedItem sg:pub.10.1186/1471-2377-4-7
157 rdf:type schema:MonetaryGrant
158 sg:journal.1024950 schema:issn 1471-2377
159 schema:name BMC Neurology
160 rdf:type schema:Periodical
161 sg:person.01031470730.29 schema:affiliation https://www.grid.ac/institutes/grid.410427.4
162 schema:familyName Hill
163 schema:givenName William D
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01031470730.29
165 rdf:type schema:Person
166 sg:person.01115504701.99 schema:affiliation https://www.grid.ac/institutes/grid.213876.9
167 schema:familyName Fagan
168 schema:givenName Susan C
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115504701.99
170 rdf:type schema:Person
171 sg:person.01146362542.60 schema:affiliation https://www.grid.ac/institutes/grid.413830.d
172 schema:familyName Hess
173 schema:givenName David C
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01146362542.60
175 rdf:type schema:Person
176 sg:person.01223307407.93 schema:affiliation https://www.grid.ac/institutes/grid.413830.d
177 schema:familyName Xu
178 schema:givenName Lin
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01223307407.93
180 rdf:type schema:Person
181 sg:person.012440130244.71 schema:affiliation https://www.grid.ac/institutes/grid.413830.d
182 schema:familyName Borlongan
183 schema:givenName Cesar V
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012440130244.71
185 rdf:type schema:Person
186 sg:person.01315561614.71 schema:affiliation https://www.grid.ac/institutes/grid.254444.7
187 schema:familyName Edwards
188 schema:givenName David
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315561614.71
190 rdf:type schema:Person
191 sg:person.01317467302.28 schema:affiliation https://www.grid.ac/institutes/grid.417993.1
192 schema:familyName Feuerstein
193 schema:givenName Giora
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317467302.28
195 rdf:type schema:Person
196 sg:person.01363476023.25 schema:affiliation https://www.grid.ac/institutes/grid.410427.4
197 schema:familyName Waller
198 schema:givenName Jennifer L
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363476023.25
200 rdf:type schema:Person
201 sg:person.0645256706.29 schema:affiliation https://www.grid.ac/institutes/grid.410427.4
202 schema:familyName Zheng
203 schema:givenName Jianqing
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645256706.29
205 rdf:type schema:Person
206 sg:pub.10.1038/417074a schema:sameAs https://app.dimensions.ai/details/publication/pub.1044223162
207 https://doi.org/10.1038/417074a
208 rdf:type schema:CreativeWork
209 sg:pub.10.1186/1471-2377-2-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015910425
210 https://doi.org/10.1186/1471-2377-2-2
211 rdf:type schema:CreativeWork
212 sg:pub.10.2165/00003088-198815060-00001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008048905
213 https://doi.org/10.2165/00003088-198815060-00001
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1002/ana.10242 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049255426
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1002/ana.10553 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043880101
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1006/nbdi.2002.0487 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006449164
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1016/j.expneurol.2003.12.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029509680
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1016/s0006-8993(02)04045-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022970218
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1016/s0006-8993(97)00580-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030416401
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1016/s0378-4347(99)00547-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001228029
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1056/nejmra022366 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031327510
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1073/pnas.1832501100 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010666269
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1073/pnas.95.26.15769 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035665084
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1073/pnas.96.23.13496 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019053748
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1089/089771503770195867 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059201655
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1093/brain/awg178 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004968542
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1161/01.str.32.6.1349 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016185576
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1212/01.wnl.0000058760.13152.1a schema:sameAs https://app.dimensions.ai/details/publication/pub.1064345067
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1523/jneurosci.22-05-01763.2002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1075009286
246 rdf:type schema:CreativeWork
247 https://doi.org/10.4049/jimmunol.166.12.7527 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074829796
248 rdf:type schema:CreativeWork
249 https://www.grid.ac/institutes/grid.213876.9 schema:alternateName University of Georgia
250 schema:name University of Georgia School of Pharmacy, 30912, Augusta, GA, USA
251 rdf:type schema:Organization
252 https://www.grid.ac/institutes/grid.254444.7 schema:alternateName Wayne State University
253 schema:name Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 48202, Detroit, MI, USA
254 rdf:type schema:Organization
255 https://www.grid.ac/institutes/grid.410427.4 schema:alternateName Augusta University
256 schema:name Biostatistics and Bioinformatics, Medical College of Georgia, 30912, Augusta, GA, USA
257 Department of Cell Biology and Anatomy, Medical College of Georgia, 30912, Augusta, GA, USA
258 Department of Neurology, Medical College of Georgia, 30912, Augusta, GA, USA
259 rdf:type schema:Organization
260 https://www.grid.ac/institutes/grid.413830.d schema:alternateName Charlie Norwood VA Medical Center
261 schema:name Department of Neurology, Medical College of Georgia, 30912, Augusta, GA, USA
262 VA Medical Center, 30904, Augusta, GA, USA
263 rdf:type schema:Organization
264 https://www.grid.ac/institutes/grid.417993.1 schema:alternateName MSD (United States)
265 schema:name Department of Cardiovascular Diseases, Merck Research Laboratories, 19486, West Point, PA, USA
266 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...